22
Mar
2019
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
14
Mar
2019
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Mar
2019
Seeing Lots of Single Cells, Up Close: Serge Saxonov of 10X Genomics on The Long Run
Serge Saxonov is today’s guest on The Long Run. Serge is the co-founder and CEO of Pleasanton, California based 10X Genomics. This privately held company, in a nutshell, is a fast-growing supplier for the genomics revolution. 10X, for those unfamiliar, makes instruments, chemical reagents for running experiments, and software that helps scientists collect and analyze various types of data. The...Read More
Share:
7
Mar
2019
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Mar
2019
Beam Therapeutics, Pushing The Edges in Base Editing, Raises $135M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Mar
2019
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
Feb
2019
Third Rock, Arch Join at Hip, Lead $191M Bet on Maze and ‘Gene Modifiers’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Feb
2019
Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run
Julia Owens is today’s guest on The Long Run. Owens is the CEO of Ann Arbor, Michigan-based Millendo Therapeutics. This company develops drugs for rare endocrine disorders. Prader-Willi syndrome, a terrible genetic disorder that causes young people to develop voracious appetites and which leads to severe obesity, is the focus of the company’s lead drug candidate. It’s entering a pivotal...Read More
Share:
20
Feb
2019
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16. Same deal with the San Francisco Cancer Summit on Apr. 18. I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the...Read More
Share:
15
Feb
2019
The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Feb
2019
The Immune Sequencing Frontier (Take 2): Harlan and Chad Robins on The Long Run
Today’s guests on The Long Run are Harlan and Chad Robins. They are brothers and co-founders of Seattle-based Adaptive Biotechnologies. Chad is the CEO, and Harlan is the head of innovation. Harlan is also a faculty member at the Fred Hutchinson Cancer Research Center just down the street from Adaptive. Senior people in pharma R&D are quite familiar with Adaptive....Read More
Share:
8
Feb
2019
Azar Angles for a Deal Pharma Can Live With, Macrogenics’ Big Break, & Sanofi Scraps 38 R&D Programs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
7
Feb
2019
Meet the Kilimanjaro Climb to Fight Cancer Team
The Kilimanjaro Climb to Fight Cancer team is ready to go. We have a full group of 28 biotech executives and investors – 14 women and 14 men – committed to climbing the highest peak in Africa this July. Working together, we’re raising $1 million for cancer research at Fred Hutch. With five months to go, we are about one-fourth...Read More
Share:
6
Feb
2019
Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle
We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment – these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer...Read More
Share:
30
Jan
2019
Finding a Way in Genomic Diagnostics: Bonnie Anderson of Veracyte on The Long Run
Bonnie Anderson is today’s guest on The Long Run. Bonnie is the CEO of Veracyte. It’s a genomic diagnostics company in South San Francisco. The company markets a line of tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte got started in 2008. Bonnie, as co-founder and CEO, was recruited by Kleiner Perkins Caufield & Byers and a...Read More
Share:
25
Jan
2019
Genentech CEO in, Editas CEO Out, & the Shutdown IPO?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
18
Jan
2019
House Dems Hunt Pharma Big Game, Shutdown Ripples, & JPM Reflections
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Jan
2019
Big Money For Glaring Global Health Needs: George Scangos on The Long Run
Today’s guest on The Long Run is George Scangos. Scangos is the CEO of San Francisco-based Vir Biotechnology. He’s best known for his last job as the CEO of Biogen, one of the industry’s biggest companies. He left that high-profile perch a little more than two years ago. Like many big company veterans, he heard the siren song to join...Read More
Share:
11
Jan
2019
Lilly Buys Loxo, Baselga Resurfaces, and Bluebird’s Gene Therapy Payment Plan
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Jan
2019
Genentech & Adaptive’s TCR Strategy, Arch’s New Cell Therapy Co, & Esperion’s Rich EU Deal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share: